Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics ...

The announcement outlines a strategic collaboration between HeartBeam and Mount Sinai to develop and validate high value, ...

Medicaid Expansion and Stage at Diagnosis, Timely Initiation and Receipt of Guideline-Concordant Treatment, and Survival Among People With Non–Small Cell Lung Cancer The CHAI platform extracted ...

Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma Our study included a broad cohort of ...

A patented, generalized drug-response foundation model trained to internalize relationships between chemical structure, tumor biology, and therapeutic response, CertisAI™ enables zero-shot prediction ...

Common early-phase pitfalls, from misaligned nonclinical strategy to gaps in CMC, bioanalysis, and species selection, can delay IND and CTA submissions. By aligning development plans with regulatory ...

Relative Energy Deficiency in Sport (REDs) has various different risk factors, numerous signs and symptoms and is heavily influenced by one’s environment. Accordingly, there is no singular validated ...

WOODLAND, CA, UNITED STATES, April 2, 2026 / EINPresswire.com / — Pheronym, an ag-biotech pest control company, announced today it has been awarded $378,000 in National Science Foundation (NSF) SBIR ...

Mushrooms Inc. (OTC: MSRM) today announced the successful early-stage validation of its mycelium-based infection detection ...

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, has been awarded a ten-year contract valued at up to $197 million by the U.S.